Composite chitosan/alginate hydrogel for controlled release of deferoxamine: a system to potentially treat iron dysregulation diseases

Giovanna Rassu, Andrea Salis, Elena Piera Porcu, Paolo Giunchedi, Marta Roldo, Elisabetta Gavini

Research output: Contribution to journalArticlepeer-review

817 Downloads (Pure)

Abstract

Recently, the potential application of deferoxamine (DFO) in several iron dysregulation diseases has been highlighted. However, DFO presents significant limitations in clinical use due to its poor absorption in the gut and very short plasma half-life. To overcome these problems, the feasibility of chitosan/alginate hydrogels as prolonged delivery systems of DFO was investigated. Hydrogel alone or co-formulated with poly(D,L-lactide-co-glycolide) microspheres were prepared and studied in vitro. The influence of the preparation methods on the performance of composite hydrogels on controlled DFO release was explored. Spray-dried microspheres based on poly(D,L-lactide-co-glycolide) were able to encapsulate DFO, a highly water soluble drug. Nevertheless, only the composite hydrogels managed to provide sustained drug release. The inclusion of microspheres into pre-formed chitosan/alginate hydrogel provided the most efficient delivery system; the drug released from microspheres is strongly entrapped in the hydrogel network and slowly released by diffusion.
Original languageEnglish
Pages (from-to)1338-1347
JournalCarbohydrate Polymers
Volume136
Early online date23 Oct 2015
DOIs
Publication statusPublished - 1 Jan 2016

Keywords

  • Composite hydrogel
  • Deferoxamine
  • Chitosan
  • Alginate
  • PLGA microparticles
  • Iron dysregulation diseases

Fingerprint

Dive into the research topics of 'Composite chitosan/alginate hydrogel for controlled release of deferoxamine: a system to potentially treat iron dysregulation diseases'. Together they form a unique fingerprint.

Cite this